360 related articles for article (PubMed ID: 26448615)
1. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial.
Zhao J; Song X; Ai X; Gu X; Huang G; Li X; Pang L; Ding M; Ding S; Lv L
PLoS One; 2015; 10(10):e0139717. PubMed ID: 26448615
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
[TBL] [Abstract][Full Text] [Related]
3. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.
Qiao Y; Yang F; Li C; Guo Q; Wen H; Zhu S; Ouyang Q; Shen W; Sheng J
Psychiatry Res; 2016 Mar; 237():83-9. PubMed ID: 26921057
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Li H; Luo J; Wang C; Xie S; Xu X; Wang X; Yu W; Gu N; Kane JM
Schizophr Res; 2014 Aug; 157(1-3):112-9. PubMed ID: 24994555
[TBL] [Abstract][Full Text] [Related]
6. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
7. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
8. Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia.
Jiang XJ; Wu FX; Zhang JP; Shi L; Hu JQ; Zhu HZ; Xiao B; Lin WC; Wen YG; Shang DW
Drug Res (Stuttg); 2018 Jul; 68(7):410-414. PubMed ID: 29482256
[TBL] [Abstract][Full Text] [Related]
9. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
10. Effect of Adjunctive Aripiprazole on Sexual Dysfunction in Schizophrenia: A Preliminary Open-Label Study.
Fujioi J; Iwamoto K; Banno M; Kikuchi T; Aleksic B; Ozaki N
Pharmacopsychiatry; 2017 Mar; 50(2):74-78. PubMed ID: 27656915
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
12. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone.
Lee BJ; Lee SJ; Kim MK; Lee JG; Park SW; Kim GM; Kim YH
Clin Psychopharmacol Neurosci; 2013 Aug; 11(2):60-6. PubMed ID: 24023549
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
14. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.
Zhong KX; Sweitzer DE; Hamer RM; Lieberman JA
J Clin Psychiatry; 2006 Jul; 67(7):1093-103. PubMed ID: 16889453
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
Yasui-Furukori N; Furukori H; Sugawara N; Fujii A; Kaneko S
J Clin Psychopharmacol; 2010 Oct; 30(5):596-9. PubMed ID: 20814333
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
17. A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia.
Kumar P B S; Pandey RS; Thirthalli J; Kumar P T S; Kumar C N
Curr Neuropharmacol; 2017 Nov; 15(8):1073-1084. PubMed ID: 28088913
[TBL] [Abstract][Full Text] [Related]
18. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
Lee BH; Kim YK; Park SH
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):714-7. PubMed ID: 16571367
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
20. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
